Clincosm LogoSign in Get a demo

Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Sponsor
OHSU Knight Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00238199
Collaborator
Sanofi (Industry)
25
Enrollment
1
Location
50
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Calcitriol may cause pancreatic cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may also help docetaxel work better by making the tumor cells more sensitive to the drug. Giving calcitriol together with docetaxel may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving calcitriol together with docetaxel works in treating patients with metastatic or locally advanced pancreatic cancer.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

OBJECTIVES:

Primary

  • Determine the time to progression in patients with metastatic or locally advanced pancreatic cancer treated with calcitriol and docetaxel.

Secondary

  • Determine the median and one-year survival of patients treated with this regimen.

  • Determine the overall response in patients treated with this regimen.

  • Determine the toxic effects of this regimen in these patients.

  • Determine the change in pancreatic cancer-induced pain in patients treated with this regimen.

OUTLINE: Patients receive oral calcitriol on days 1, 8, and 15 and docetaxel IV over 15-30 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Study of Calcitriol-Enhanced Docetaxel in Patients With Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer
Study Start Date :
Jun 1, 2002
Actual Primary Completion Date :
Aug 1, 2006
Actual Study Completion Date :
Aug 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Time to progression []

Secondary Outcome Measures

  1. Median and one-year survival []

  2. Overall response []

  3. Toxicity []

  4. Change in pancreatic cancer-induced pain []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
DISEASE CHARACTERISTICS:

  • Diagnosis of pancreatic cancer

  • Locally advanced or metastatic disease

PATIENT CHARACTERISTICS:

Age

  • Over 18

Performance status

  • Eastern Cooperative Oncology Group (ECOG) 0-2

Life expectancy

  • Not specified

Hematopoietic

  • White blood cell (WBC) > 3,000/mm^3

  • Absolute neutrophil count > 1,500/mm^3

  • Platelet count > 100,000/mm^3

  • Hemoglobin ≥ 8.0 g/dL (transfusion allowed)

Hepatic

  • Bilirubin < 1.5 times upper limit of normal (ULN)

  • Alkaline phosphatase (AP) < 5.0 times ULN

  • Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 2.5 times ULN (if AP < 2.5 times ULN) OR

  • ALT and AST < 1.5 times ULN (if AP > 2.5 times ULN and < 5.0 times ULN)

Renal

  • Creatinine < 1.3 mg/dL

  • Calcium < 10.5 mg/dL

  • Phosphate < 4.7 mg/dL

  • No kidney stones within the past 5 years

  • No history of hypercalcemia

Cardiovascular

  • No myocardial infarction within the past 3 months

  • No uncontrolled heart failure with a known ejection fraction < 30%

  • No other significant heart disease

Other

  • Not pregnant or nursing

  • Fertile patients must use effective contraception

  • No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80

  • No peripheral neuropathy ≥ grade 2

  • No comorbid condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior chemotherapy for metastatic disease

  • No prior chemoradiotherapy for locally advanced disease

  • No prior adjuvant docetaxel

  • Other prior adjuvant chemotherapy allowed

Endocrine therapy

  • Not specified

Radiotherapy

  • See Chemotherapy

  • More than 2 weeks since prior radiotherapy

Surgery

  • More than 30 days since prior investigational surgery

Other

  • More than 7 days since prior and no concurrent digoxin or thiazide diuretic therapy

  • More than 30 days since prior investigational therapy

  • No concurrent magnesium-containing antacids, bile resin-binding drugs, or calcium supplements

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oregon Health & Science University Cancer Institute Portland Oregon United States 97239-3098

Sponsors and Collaborators

  • OHSU Knight Cancer Institute
  • Sanofi

Investigators

  • Principal Investigator: Charles D. Blanke, MD, FACP, OHSU Knight Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00238199
Other Study ID Numbers:
  • CDR0000445077
  • OHSU-GIM-02007-L
  • OHSU-1104
First Posted:
Oct 13, 2005
Last Update Posted:
Apr 24, 2015
Last Verified:
Apr 1, 2015
Keywords provided by , ,
stage III pancreatic cancer
stage IV pancreatic cancer
Additional relevant MeSH terms:
Pancreatic Neoplasms
Calcitriol
Docetaxel

Study Results

No Results Posted as of Apr 24, 2015